Micromanaging hepatitis C virus.

Hepatitis C virus (HCV), a positive-stranded RNA flavivirus, persistently infects approximately 170 million persons worldwide and can lead to cirrhosis and hepatocellular carcinoma. The approval of two HCV protease inhibitors, telaprevir and boceprevir, by the Food and Drug Administration (FDA) in 2011 dramatically improved therapy. These drugs are used in combination with pegylated interferon alfa and ribavirin.1 Although protease inhibitors have greatly enhanced the sustained viral response rate, these inhibitors are active against only the dominant viral genotype found in North America and Europe (genotype 1), and about a third of patients with genotype 1 infection do not have sustained . . .

[1]  S. Kauppinen,et al.  Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice , 2011, EMBO molecular medicine.

[2]  P. Sarnow,et al.  Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex , 2011, Proceedings of the National Academy of Sciences.

[3]  S. Lemon,et al.  Stabilization of hepatitis C virus RNA by an Ago2–miR-122 complex , 2012, Proceedings of the National Academy of Sciences.

[4]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[5]  S. Lemon,et al.  Competing and noncompeting activities of miR-122 and the 5′ exonuclease Xrn1 in regulation of hepatitis C virus replication , 2012, Proceedings of the National Academy of Sciences.

[6]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[7]  D. Gaudet,et al.  Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease , 2012, Circulation.

[8]  Judy Lieberman,et al.  RNA interference targeting Fas protects mice from fulminant hepatitis , 2003, Nature Medicine.

[9]  P. Sarnow,et al.  Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA , 2005, Science.

[10]  P. Belperio,et al.  A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  M. Caligiuri,et al.  Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. , 2012, The Journal of clinical investigation.

[12]  Krista A. Zanetti,et al.  Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.

[13]  Michael Adler,et al.  Response-guided telaprevir combination treatment for hepatitis C virus infection. , 2011, The New England journal of medicine.

[14]  A. Silahtaroglu,et al.  Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver , 2007, Nucleic acids research.

[15]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[16]  S. Kauppinen,et al.  Treatment of HCV infection by targeting microRNA. , 2013, The New England journal of medicine.

[17]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[18]  Hsien-Da Huang,et al.  MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. , 2012, The Journal of clinical investigation.

[19]  Anna Persson,et al.  Preliminary study of two antiviral agents for hepatitis C genotype 1. , 2012, The New England journal of medicine.

[20]  E. Olson,et al.  Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure , 2011, Circulation.

[21]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[22]  Catherine L Jopling,et al.  Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. , 2008, Cell host & microbe.

[23]  W. Filipowicz,et al.  Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy , 2009, Nature Medicine.

[24]  K. Chayama,et al.  Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders , 2012, Hepatology.

[25]  Jacques Fellay,et al.  IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C , 2010, Hepatology.

[26]  P. Terasaki,et al.  Liver transplantation in the United States. , 2005, Clinical transplants.

[27]  Hsien-Da Huang,et al.  MicroRNA‐122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma , 2009, Hepatology.

[28]  William M. Lee,et al.  Outcome of sustained virological responders with histologically advanced chronic hepatitis C , 2010, Hepatology.

[29]  M. Manns,et al.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.

[30]  S. Thorgeirsson,et al.  Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties , 2009, Oncogene.

[31]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[32]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[33]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[34]  An Overview of the Clinical Safety Experience of First- and Second-Generation Antisense Oligonucleotides , 2007 .

[35]  I. Jacobson,et al.  Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Mark Graham,et al.  miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. , 2006, Cell metabolism.

[37]  Robert A. Weinberg,et al.  Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model , 2010, Nature Biotechnology.

[38]  J. Bukh,et al.  MicroRNA-122 antagonism against hepatitis C virus genotypes 1–6 and reduced efficacy by host RNA insertion or mutations in the HCV 5′ UTR , 2011, Proceedings of the National Academy of Sciences.

[39]  S. Kauppinen,et al.  LNA-mediated microRNA silencing in non-human primates , 2008, Nature.

[40]  Michael Niepmann,et al.  microRNA-122 stimulates translation of hepatitis C virus RNA , 2008, The EMBO journal.

[41]  Peter Schirmacher,et al.  MicroRNA gene expression profile of hepatitis C virus–associated hepatocellular carcinoma , 2007, Hepatology.

[42]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.